SCHEMBL110460

SCHEMBL110460

NCc1c(Cl)cccc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.64
DPP4 P27487 2/20 0.57
PNMT P11086 3/20 0.56
AKR1B1 P15121 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2A6 P11509 1/20 0.43
LMNA P02545 2/20 0.42
TSHR P16473 1/20 0.42
ADRA2A P08913 2/20 0.42
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42
HTR1A P08908 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
MAOA P21397 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7895201 0.97 TAAR1 (0.61) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
SCHEMBL932553 0.85 PNMT (0.67) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
SCHEMBL30528615 0.85 TAAR1 (0.54) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
SCHEMBL2833792 0.85 TAAR1 (0.54) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
SCHEMBL113076 0.83 TAAR1 (0.73) TAAR1DPP4PNMTSMN1; SMN2MEN1
SCHEMBL1127909 0.83 TAAR1 (0.52) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
SCHEMBL6822756 0.83 TAAR1 (0.52) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
SCHEMBL19825564 0.83 TAAR1 (0.52) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
SCHEMBL31737298 0.83 TAAR1 (0.52) TAAR1DPP4PNMTAKR1B1SMN1; SMN2
Hydrochloric Acid SCHEMBL11150443 0.81 TAAR1 (0.70) TAAR1DPP4PNMTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510429-A Compound containing methyl isoxazole structure, and preparation method and application thereof 中国农业大学 2024-02-06 CN claimed
CN-112625039-A Pyrroloquinoline compound and synthesis method thereof 湘潭大学 2021-04-09 CN claimed
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
US-9884839-B2 Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 ELEXOPHARM GMBH (DE) 2018-02-06 US claimed
EP-3089969-A2 INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASES TYPE 1 AND TYPE 2 Elexopharm GmbH (DE) 2016-11-09 EP claimed
US-20160318895-A1 Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 ELEXOPHARM GMBH (DE) 2016-11-03 US claimed
CN-102388060-B Actagardine derivatives NOVACTA BIOSYSTEMS LTD 2014-09-10 CN claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
CN-101410366-A Substituted bicyclic ring derivatives and uses thereof ASAHI KASEI PHARMA CORP (JP) 2009-04-15 CN claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
US-7253171-B2 Urea derivatives as integrin α4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-07 US claimed
US-20040142982-A1 Urea derivatives as integrin alpha 4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2004-07-22 US claimed
EP-1383750-A2 UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2004-01-28 EP claimed
US-6649799-B2 Catalytic hydrogenation using a Raney catalyst in the form of hollow bodies; hexamethylenediamine from adiponitrile DEGUSSA AG (DE) 2003-11-18 US claimed
EP-1343749-A2 METHOD FOR PRODUCING PRIMARY AND SECONDARY AMINES BY HYDROGENATING NITRILES AND IMINES Degussa AG (DE) 2003-09-17 EP claimed
US-20020173676-A1 Method for producing primary and secondary amines by hydrogenation of nitriles and imines DEGUSSA AG (DE) 2002-11-21 US claimed
WO-2002057242-A2 UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS ALMIRALL PRODESFARMA, S.A. (ES) 2002-07-25 WO claimed
WO-2002051791-A2 METHOD FOR PRODUCING PRIMARY AND SECONDARY AMINES BY HYDROGENATING NITRILES AND IMINES DEGUSSA AG (DE) 2002-07-04 WO claimed
EP-0363643-A1 Pesticides based on partially different 2-aryl-substituted 1-10-phenanthrolines, and their preparation BAYER AG (DE) 1990-04-18 EP claimed
EP-0282893-A2 Pesticides based on 1,10-phenanthrolines BAYER AG (DE) 1988-09-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R TAAR1 1127/4885DPP4 4105/4885PNMT 3102/4885
US-20160318895-A1 Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 HSD17B1, HSD17B2, HSD17B3 TAAR1 3770/4885DPP4 1188/4885PNMT 3041/4885
US-20040142982-A1 Urea derivatives as integrin alpha 4 antagonists ITGA4, ITGB4, ITGA1 TAAR1 2288/4885DPP4 1678/4885PNMT 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.